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2ABSTRACT
Purpose: The aim was to assess anterior pituitary hormone levels during the acute
phase of aneurysmal subarachnoid hemorrhage (aSAH) and analyze the possible
association with the clinical condition and outcome.
Material and Methods: Forty patients with aSAH whose aneurysm was secured by
endovascular coiling were enrolled. Basal secretions of cortisol,, testosterone,
luteinising hormone, prolactin and sex hormone binding globulin levels were
measured up to 14 days after the incident.
Results: Main finding was that hypocortisolism was rare whereas testosterone
deficiency was common in male patients. Furthermore, various other hormone
deviations were frequent and there was wide inter-individual variability. We found no
association between delayed cerebral ischemia, outcome of the patients or aneurysm
location and hormone abnormalities, while both Hunt & Hess and Fisher grade were
associated with low prolactin levels. Hunt & Hess 5 was associated with low prolactin
concentration when compared to grades 1 (OR=4.81, 95% CI 1.15-20.14, p=0.03), 3
(OR 7.73, 95% CI 1.33-45.01, p=0.02) and 4 (OR= 6.86 95% CI 1.28-26.83, p=0.02).
Fisher grade 4 was associated with low prolactin concentration when compared to
grades 3 (OR 3.37, 95% CI 1.06-10.73, p=0.03) and 2 (OR 9.71, 95% CI 1.22-77.10,
p=0.04).
Conclusion: Deviations from normal and huge inter-individual differences are
common in hormone levels during acute phase of aSAH. Routine assessment of
anterior pituitary function in the acute phase of aSAH is not warranted. During the
follow up in the outpatient clinic, hormone concentrations were not measured, which
would have brought more long-term perspective into our findings.
3INTRODUCTION
Previous studies have indicated that approximately half of the patients with
aneurysmal subarachnoid hemorrhage (aSAH) have low levels of anterior pituitary
hormones and an anterior pituitary dysfunction (1,2). In the chronic phase
corticotropin and growth hormone deficiencies are most prevalent whereas sex
hormone deficiencies are more infrequent (3,4). These deficiencies may contribute to
morbidity and poor cognitive performance after aSAH (4,5). The etiology of hormone
deficiencies is still unknown, albeit ischemia and brain odema have been postulated to
diminish vulnerable blood supply to hypothalamus and pituitary gland, leading to
their functional impairment (6).
Few previous studies have evaluated anterior pituitary hormone levels during the
acute phase of aSAH. These studies have demonstrated that hypocortisolism is rare
whereas low concentrations of thyroid hormone, growth hormone and gonadotropins
are more common (7-12)
Our aim was to assess anterior pituitary hormone levels during the acute phase of
aSAH. We measured cortisol, testosterone, luteinizing hormone (LH), prolactin (PRL)
and sex hormone binding globulin (SHBG) levels for 14 days after the haemorrhage.
To our knowledge, this study provides to date the longest evaluation of hormonal
changes during the acute phase. In addition, we were interested on the possible
association between the hormone levels and patient outcome.
4MATERIAL AND METHODS
Forty patients with aSAH and whose aneurysm was secured by endovascular coiling
were enrolled into the study. The study was approved by the Ethics Committee of the
Hospital District of Southwest Finland (approval number: 56/180/2009). Patients or
their next of kin were given both written and oral information about the study and
written informed consent was obtained. Patients who had previous hormone
deficiencies, were on corticosteroid treatment or were moribund (brain death) were
excluded from the study. Patients who were treated by surgical clipping were also
excluded as they were given intravenous betamethason before and after craniotomy.
The amount of blood in computed tomography scans were estimated using Fisher
scale (13), where 1 = no blood detected, 2 = diffuse or vertical layers < 1 mm thick, 3
= localised clot and/or vertical layer ³ 1 mm and 4 = intracerebral or intraventricular
clot with diffuse or no SAH.  Clinical condition was scored using Hunt & Hess grades
(14) where 1 = asymptomatic, mild headache, slight nuchal rigidity, 2 = moderate to
severe headache, nuchal rigidity, no neurologic deficit other than cranial nerve palsy,
3 = drowsiness/confusion, mild focal neurologic deficit, 4 = stupor, moderate-severe
hemiparesis, 5 = coma, decerebrate posturing.
All aSAH patients had either intravenous or oral nimodipine. Total intravenous
anesthesia including propofol, remifentanil and rocuronium were used for the coiling
procedure. Hypertension and normovolemia were part of the routine treatment
modalities to prevent delayed cerebral ischemia (DCI). Patients needing
pharmacological treatment to achieve hypertension were given noradrenaline.
Blood samples for the determination of serum hormone concentrations were obtained
between 7-8 am on the next morning after the hemorrhage (day 1), and at the same
5time on days 3, 5, 7, 10 and 14. All the samples were analyzed in the laboratory of
Turku University Hospital. Electrochemiluminescence immunoassay method was
used to measure plasma cortisol (reference interval 150-650 nmol/l), PRL (female
102-496 mU/l and male 86-324 mU/l), LH (male 1.7-8.6 U/l and female over 50 years
7.7-59 U/l) and SHBG (female 26-119 nmol/l and male 15-48 nmol/l). The
testosterone/SHBG ratio was calculated in male patients (reference interval 410-
1400). Serum testosterone was measured by radioimmunoassay with reference
interval for male 10-33 nmol/l and female 0.6-2.4 nmol/l. Although the lowest plasma
cortisol reference value was 150 nmol/l, the current literature suggests that diagnostic
criteria for hypocortisolism in critical illness is random cortisol level < 10 g/dl (275
nmol/l) (15) and this criteria was applied.
Clinical condition was graded according to Hunt & Hess, and Fisher grade was used
to rank the amount of blood in the first CT scan. Patient outcome at 6 months was
graded using Glasgow outcome scale (GOS), which was dichotomized into favourable
(GOS 5 and 4) and unfavourable (GOS 3, 2 and 1). Outcome was assessed at 6
months after aSAH using Glasgow Outcome Scale (GOS) (16), where 1 = death, 2 =
persistent vegetative state, 3 = severe disability, 4 = moderate disability and 5 = good
recovery. Outcome was further dichotomized and GOS 4-5 was classified as
favourable and GOS 1-3 as unfavourable outcome.
Statistical analysis was done with SAS System for Windows, version 9.3 (SAS
Institute Inc., Cary, NC, USA). Repeated measures analysis of variance (ANOVA)
with compound symmetry covariance structure was used to analyse changes in the
hormone concentrations during the study period. Dunnett’s method was used to
compare the hormone concentrations on the follow-up days with day 1. Only cortisol
levels were normally distributed. After logarithmic transformation all other variables
6were normally distributed, enabling ANOVA analysis. Logistic regression analysis
was used to analyse associations between abnormally low hormone concentrations
and Hunt & Hess, Fisher grading, aneurysm location and DCI. Generalized estimating
equations (GEE) with exchangeable correlation structure were used in logistic models
to account for the correlation between repeated measurements. Demographic and
cortisol data is presented as means and standard deviations (SD) and other data as
medians interquartile ranges (IQR). P-value < 0.05 was considered statistically
significant.
7RESULTS:
The demographic data of our patients with the Fisher and Hunt & Hess grades are
summarized in Table 1. Altogether, 26 women and 14 men were recruited. The mean
age was 58.1 (10.2) years. In 32 patients the aneurysm was located in the anterior and
in 8 patients in the posterior circulation. GOS at six months after the incident was
favourable in 22 and unfavourable in 14 patients. Outcome data was missing for four
patients.
There was only one female patient, who had completely normal hormonal findings
during the entire study period. All other 39 patients had at least one abnormal
laboratory finding. There was no association between abnormal hormone levels and
dichotomized outcome (favourable vs. unfavourable) of the patients or between
aneurysm location.
Nineteen patients developed DCI. In eight patients the diagnosis was based on clinical
deterioration, in two patients the diagnosis was confirmed during conventional
angiography, in eight patients based on a new infarct seen on computed tomography
and in one patient the diagnosis was made using transcranial Doppler. DCI appeared
5.5 (3.0) days after aSAH. DCI was not associated with hormone abnormalities (data
not shown).
Serum cortisol
Most of the patients had high serum cortisol levels, above 650 nmol/l, during the first
five days. On the first morning after the ictus, 20/37 (the first morning sample was not
obtained from three patients) patients had cortisol levels above 650 nmol/l. Only 4/37
patients had cortisol levels lower than 275 nmol/l. However, cortisol replacement
8therapy was given to two patients whose cortisol level was below 150 nmmol/l. The
cortisol levels decreased slowly after the ictus and this decrease was statistically
significant during the study period (p=0.0009) (Figure 1). The decrease was
significant on days 10 and 14 compared to day 1 (p=0.006 and p=0.0003,
respectively). Mean and SD cortisol levels are presented on Table 2.
Serum testosterone male
Twelve out of 14 males had serum testosterone deficiency (<10 nmol/l) at least twice
during the measurements. Four of these 12 patients showed testosterone deficiency in
all seven measurements, whereas 3/12 patients had low levels in five time points and
3/12 patients in four time points. Median testosterone levels are presented on Table 2
and figure 2 displays the mean profiles for male testosterone levels. In the whole
study population, the mean testosterone/SHGB ratios (reflects biologically active
testosterone) were below lower limit (410) throughout the study period, Figure 2.
Luteinizing hormone in female patients
Sixteen female patients had at least one low LH concentration during the study
period. One of these patients had low levels in all measurements whereas four patients
had low concentrations in five measurements. Two patients had low concentrations in
three, four patients had low concentrations in two and five patients had low
concentrations in one measurement, respectively.
Luteinizing hormone in male patients
Two patients had low LH levels twice and five patients had a single low LH
measurement. These low levels had no discernible pattern in the timing of decreased
testosterone levels. Only three patients had elevated LH concentrations.
9Prolactin
There was an association between low prolactin levels and Hunt & Hess grades as
well as with Fisher grades. Hunt & Hess grade 5 was associated with low
concentration when compared to grades 1 (OR=4.81, 95% CI 1.15-20.14, p= 0.03), 3
(OR 7.73, 95% CI 1.33-45.01, p=0.02) and 4 (OR= 6.86 95% CI 1.28-26.83, p=0.02).
Fisher grade 4 was also associated with low prolactin concentration when compared
to grades 3 (OR 3.37, 95% CI 1.06-10.73, p=0.03) and 2 (OR 9.71, 95% CI 1.22-
77.10, p=0.04). Median prolactin levels are shown in Table 3.
Prolactin in female patients
One patient had low prolactin levels during four measurements. One patient had low
levels in three measurements and one patient in two measurements. Single low levels
were observed in six patients.
High values were found four times in one patient, three times in one additional patient
and twice in two patients. Interestingly, two patients had once both low and high
values.
Prolactin in male patients
One male had low levels in three measurements and one patient in two measurements.
Two patients had isolated low measurements. High prolactin values were seen in one
patient in all six measurements and one patient had high values twice. Four patients
had only one low prolactin value.
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DISCUSSION
Our main finding was that hypocortisolism was rare while slightly elevated cortisol
levels were observed frequently in our patients. Moreover testosterone deficiency in
male patients was very common during the acute phase of aSAH. Mild fluctuations in
the other anterior pituitary hormones were also observed frequently. These
fluctuations did not show any distinct temporal pattern after the onset of aSAH but
could at least in part represent the pulsatile secretion of many of the hormones. On
average, we observed no association between the outcome of the patients and
hormone levels. However, both Hunt & Hess and Fisher gradings were associated
with low prolactin levels. Furthermore, there was no association between aneurysm
location and hormone levels, which is in accordance with others (10). Our results
regarding the outcome are not in line with previous studies, which have observed
correlations with worse clinical status and outcome with other hormonal
abnormalities(17-19). Dopamine (20,21) and etomidate (22) are known to have effect
on hormone secretion but the observed hormone abnormalities in our study were not
attributed to them as dopamine or etomidate were not used in any of our patients.
Cortisol
High cortisol levels in our patients are in accordance with other studies (7,9,11). The
early response is likely due to stress-induced upregulation of CRH and ACTH but the
later elevation could be caused by decreased degradation of cortisol, as suggested in a
mixed population of critically ill patients (23-25). Unfortunately, we could not
confirm this by ACTH measurements in this study. 5% of our patients had low
cortisol level and despite being rare, adrenal insufficiency should be suspected if the
patient is hemodynamically unstable and is in need of high doses of vasopressors.
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Although adrenal insufficiency is uncommon during the acute phase, there is some
indication that adrenocortical insufficiency may be present after three months to one
year after the haemorrhage (4,26).
Luteinizing hormone
Most women in our study were postmenopausal as the mean age of women was 59.
However, due to the bleeding, patients were confused and disorientated, had loss of
short term memory or consciousness, it was difficult and impossible to obtain reliable
information regarding the timing of their last periods or ceased periods. In addition,
due to afore mentioned reasons and lack of previous medical treatment in our
hospital, we did not have available data regarding possible hormone replacement
therapy or contraception.
Prolactin
Altogether 16 (40%) patients had high prolactin levels. Critical illness and stress are
known to increase prolactin levels, most likely due to increased adrenergic activity of
the hypothalamus (27). In addition, it has been suggested that increased prolactin
levels could be associated with epileptic seizures (28,29). However, none of these 16
patients had seizures nor were they on dopamine antagonist medication, which could
also explain the increased secretion. It has been reported previously that during acute
phase of aSAH, 31% of patients, have increased prolactin levels (17). However, it is
unclear whether these patients showed epileptic seizures or not as this was not
reported. Perhaps generalised stress reaction and possible oedema compressing the
hypothalamus and/or pituitary stalk leads to increased prolactin secretion. Another
possible explanation for increased prolactin levels in our patients is the use of opioids
(30) where as antipsychotics or antidepressants (30) were not used in  our patients.
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Real prolactin deficiency is uncommon and is usually related to other pituitary
hormone deficiencies (31). 13 (32.5%) patients had low prolactin concentrations,
which however were not related to other hormone concentrations. Although the most
severe form of aSAH presentation correlated with low prolactin concentrations, the
meaning or cause of the low prolactin concentration in our study remains unclear.
Testosterone
Low testosterone concentrations were observed in most of the male patients and
biologically active testosterone (testosterone/SHBG ratio) was also low.
Hypogonadotropic hypogonadism is unlikely and secondary hypogonadism more
likely as low LH concentrations were infrequent (31). Similar findings have been
observed also previously and these changes seem to be transient (17), probably
resulting from an illness induced stress reaction and direct suppression of testosterone
production by stress-induced cytokines (32).
Limitations
Our study has some limitations. First of all, we collected samples only from 40
patients and our results apply only to aSAH patients whose aneurysms were coiled.
On the other hand this rules out the possible effect of craniotomy and surgical stress
on our findings. Other studies have included also patients who had undergone
craniotomy and clipping (4,12,17,18) and it is possible that surgery may have affected
hormone profiles (33) in these studies. In future studies both types of treatment
modalities should be taken into account during the analysis and interpretation of the
results. Secondly, we measured only basal hormone secretion whereas additional
stimulated hormone concentrations could have given further insight into pituitary
function in these patients. Lastly, we did not measure hormone concentrations during
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the follow up in the outpatient clinic, which would have brought more long-term
perspective into our findings. This would have revealed those patients who would
have developed hormonal deficiencies at later stage, and their possible correlation
with the long-term co-morbidities of aSAH such as neuropsychological deficiencies
or depression. On the other hand, some studies have demonstrated that acute phase
abnormalities do not predict the development of pituitary dysfunctions at the later
stage (1,34). Many of the aSAH patients in our study came from other hospital
districts without neurosurgical facilities and their follow up is organised locally in
their own hospital district by neurologists.
Anterior pituitary hormone concentrations during the acute phase of aSAH have been
evaluated also previously. However, in these previous studies the sampling time has
been shorter and/or only one sample obtained, varying from a single 1st day sample
up to 15 days (12,17-19). We obtained samples at six time points and measured
hormone concentrations up to 14 days post ictus. Based on our results, apart from
ACTH-cortisol axis, it seems unnecessary to measure anterior pituitary function
routinely during the onset of aSAH as the various hormone concentrations vary even
daily within the subjects. However, their assessment at later stage during the long-
term follow-up should be considered in those patients who have not recovered as
expected.
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Table 1. Demographics of the data
Table 1. Demographics of the data
Age all, mean (SD) 58.1 (10.2)
Age female, mean (SD) 59.2 (9.8)
Age male, mean (SD) 56.0 (10.9)
Smokers 15 (37.5 %)
Non smokers 14 (35.0 %)
Smoking status not known 11 (27.5%)
Hypertension 12 (30%)
Aneurysm location:
A. Comm. Ant. 13 (32.5%)
A. Cerebri Med 11 (27.5%)
A. Carotis Int 5 (12.5%)
A. Basilaris 5 (12.5%)
A. Pericallosa 3 (7.5%)
A. Vertebralis 2 (5.0%)
A. Comm. Post. 1 (2.5%)
Hunt & Hess
Grade I 11 (27.50%)
Grade II 9 (22.5%)
Grade III 5 (12.5%)
Grade IV 7 (17.5%)
Grade V 8 (20.0%)
Fisher grade
Diffuse or vertical layers < 1 mm thick 7 (17.5%)
Localised clot/vertical layer ≥ 1 mm 18 (45.0%)
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Intracerebral or intraventricular clot with diffuse or no
SAH
15 (37.5%)
Glasgow Outcome Scale
1 death 8 (22.2%)
2 persistent vegetative state 1 (2.8%)
3 severe disability 5 (13.9%)
4 moderate disability 7 (19.4%)
5 good recovery 15 (41.7%)
Glasgow Outcome Scale dichotomised
1-3 unfavourable recovery 14 (38.9%)
4-5 good recovery 22 (61.1%)
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Table 2. Mean and SD of cortisol and numbers of patients with < 275 nmol/l cortisol
levels. Median and IQR (interquartile range) of testosterone levels. Reference values
are presented in parenthesis.
Cortisol (150-600
nmol/l)
Cortisolo < 275 nmol/l Testosterone male (10-33
nmol/l)
DAY N Mean (SD) N N Median (IQR)
1 36 758 (403) 36 4 12 8.15 (3.65-
14.30)
3 36 600 (278) 36 5 13 4.70 (2.95-
6.40)
5 35 665 (301) 35 4 13 5.00 (2.70-
9.00)
7 34 590 (277) 34 3 11 4.10 (2.40-
8.20)
10 33 520 (239) 33 6 13 5.10 (2.85-
8.55)
14 20 412 (187) 20 6 7 6.30 (3.20-
9.10)
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Table 3. Median and IQR (interquartile range) of prolactin levels. Reference values
are presented in parenthesis.
Prolactin female (102-496 mU/l) Prolactin male (86-324 mU/l)
Day N Median (IQR) N Median (IQR)
1 23 242 (102-354) 12 150 (98-222)
3 24 218 (111-370) 13 118 (96-201)
5 23 249 (158-394) 13 202 (156-272)
7 24 219 (162-372) 11 268 (181-302)
10 21 333 (203-469) 13 273 (207-351)
14 13 370 (286-517) 7 278 (240-443)
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Figure 1. Mean (standard error) cortisol (nmol/l) levels during the study period.
Reference values are presented with dashed lines. The decrease in cortisol levels after
the ictus was statistically significant (p=0.009). The decrease was significant on days
10 and 14 compared to day 1 (p=0.006 and p=0.0003, respectively).
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Figure 2. Mean (standard error) profiles for male testosterone levels (mmol/l) (A) and
testosterone/SHBG values (B). Reference values are presented with dashed lines. The
change in testosterone levels or testosterone/SHBG values was not significant (p =
0.12 and p=0.20, respectively).
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3Table 2. Mean and SD of cortisol and number of patients with < 275 nmol/l cortisol levels. Median and IQR (interquartile range) of testosterone levels.
Reference values are presented in parenthesis.
Cortisol (150-600 nmol/l) Cortisol < 275 nmol/l Testosterone male (10-33 nmol/l)
DAY N Mean (SD) N N Median (IQR)
1 36 758 (403) 36 4 12 8.15 (3.65-14.30)
3 36 600 (278) 36 5 13 4.70 (2.95-6.40)
5 35 665 (301) 35 4 13 5.00 (2.70-9.00)
7 34 590 (277) 34 3 11 4.10 (2.40-8.20)
10 33 520 (239) 33 6 13 5.10 (2.85-8.55)
14 20 412 (187) 20 6 7 6.30 (3.20-9.10)
4Table 3. Median and IQR (interquartile range) of prolactin levels. Reference values are presented in parenthesis.
Prolactin female (102-496 mU/l) Prolactin male (86-324 mU/l)
Day N Median (IQR) N Median (IQR)
1 23 242 (102-354) 12 150 (98-222)
3 24 218 (111-370) 13 118 (96-201)
5 23 249 (158-394) 13 202 (156-272)
7 24 219 (162-372) 11 268 (181-302)
10 21 333 (203-469) 13 273 (207-351)
14 13 370 (286-517) 7 278 (240-443)
Figure 1. Mean (standard error) cortisol (nmol/l) levels during the study period. Reference values are presented with dashed lines. The decrease in cortisol
levels after the ictus was statistically significant (p=0.009). The decrease was significant on days 10 and 14 compared to day 1 (p=0.006 and p=0.0003,
respectively).
Figure 2. Mean (standard error) profiles for male testosterone levels (mmol/l) (A) and testosterone/SHBG values (B). Reference values are presented with
dashed lines. The change in testosterone levels or testosterone/SHBG values was not significant (p = 0.12 and p=0.20, respectively).
